Videos

Michael Mrochen, President speaks for Allotears during the Innovative Showcase at OIS@AAO 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv.

Aerpio’s Kevin Peters, MD, discusses how his company’s lead VE-PTP inhibitor/Tie2 activator AKB-9778 enhances both vascular stability and fluid outflow, making it a potential candidate…

Allegro’s Vicken Karageozian, MD, talks about the risuteganib phase 2 for intermediate dry AMD (showing a “robust reversal of vision loss”), their dry eye drug…

Glenn Sblendorio, CEO & President, speaks about IVERIC bio’s plans to develop gene therapies for orphan inherited retinal diseases. Plans include a phase 1/2 in…

Ken Mills, CEO speaks for REGENXBIO during the Public Company Spotlight at OIS@AAO 2019. REGISTER for our next ophthalmology conference today http://bit.ly/2yFA6cv.

 Megan Baldwin, PhD, CEO & Managing Director speaks for OPTHEA during the Public Company Spotlight at OIS@AAO 2019. REGISTER for our next ophthalmology conference…

 Antony Mattessich of Ocular Therapeutix discusses the company’s first launch (Dextenza), the ins and outs of drug delivery technology and formulations, and what the…

Public gene therapy company Adverum Biotechnologies’ Aaron Osborne, MBBS MRCOpth, discusses ADVM-022, an intravitreal gene therapy for VEGF-driven retinal diseases. Aaron Osborne, MD, Chief Medical…